R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study

Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B‐cell lymphoma (DLBCL). These studies prompted our group...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hematological oncology 2008-03, Vol.26 (1), p.27-32
Hauptverfasser:	Rueda, Antonio, Sabin, Pilar, Rifá, Juli, Llanos, Marta, Gómez-Codina, José, Lobo, Francisco, García, Ramón, Herrero, Joaquin, Provencio, Mariano, Jara, Carlos
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Murine-Derived Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use CHOP Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Doxorubicin - administration & dosage Doxorubicin - adverse effects Female Humans lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Male Middle Aged Patient Compliance Pilot Projects Prednisone - administration & dosage Prednisone - adverse effects Prospective Studies Rituximab Vincristine - administration & dosage Vincristine - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B‐cell lymphoma (DLBCL). These studies prompted our group (GOTEL) to evaluate prospectively in a pilot study the feasibility and efficacy of R‐CHOP‐14 in patients with DLBCL. Patients (
ISSN:	0278-0232 1099-1069
DOI:	10.1002/hon.829